| 70.115 -2.725 (-3.74%) | 06-26 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 87.3 |
1-year : | 101.97 |
| Resists | First : | 74.75 |
Second : | 87.3 |
| Pivot price | 61.44 |
|||
| Supports | First : | 61.43 |
Second : | 53.2 |
| MAs | MA(5) : | 68.67 |
MA(20) : | 60.45 |
| MA(100) : | 62.88 |
MA(250) : | 47.58 |
|
| MACD | MACD : | 1.6 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 86.7  |
D(3) : | 90.4 |
| RSI | RSI(14): 63 |
|||
| 52-week | High : | 75.5 | Low : | 23.64 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CGON ] has closed below upper band by 13.4%. Bollinger Bands are 124.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 73.55 - 73.82 | 73.82 - 74.04 |
| Low: | 65.18 - 65.5 | 65.5 - 65.75 |
| Close: | 72.32 - 72.85 | 72.85 - 73.28 |
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Fri, 26 Jun 2026
CG Oncology, Inc. Actuals & Estimates (BOATS:CGON) - TradingView
Fri, 26 Jun 2026
CGON Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 25 Jun 2026
CG Oncology (NASDAQ: CGON) director sells 5,000 shares, exercises options - Stock Titan
Thu, 25 Jun 2026
CG Oncology Inc (CGON) Institutional Confidence - TradingKey
Tue, 23 Jun 2026
CG Oncology (NASDAQ: CGON) director exercises options and sells 5,000 shares - Stock Titan
Mon, 22 Jun 2026
CGON (NASDAQ: CGON) files notice to sell 6,000 shares on 06/22/2026 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -106 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 8.82e+007 (%) |
| Held by Institutions | 6.582e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3544e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.34 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 130.1 % |
| Return on Equity (ttm) | -14.5 % |
| Qtrly Rev. Growth | 5.07e+006 % |
| Gross Profit (p.s.) | 584.57 |
| Sales Per Share | -30.96 |
| EBITDA (p.s.) | -1.675e+008 |
| Qtrly Earnings Growth | -2.127e+008 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -29.85 |
| Price to Sales | -2.26 |
| Price to Cash Flow | 0 |
| Dividend | 9.81e+006 |
| Forward Dividend | 9.22e+006 |
| Dividend Yield | 14046400% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|